Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06617546 · ClinicalTrials.gov registry record · Phase 1
SAD and MAD Study of FTX-101 in Healthy Male Subjects
A Phase 1 study, sponsored by Find Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT06617546 is a Phase 1 study that was terminated before completion, run by Find Therapeutics. The registered enrollment target is 49 participants.
The verdict
NCT06617546, a Phase 1 study, was terminated before completion, sponsored by Find Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects. The study will include the following 2 parts: * Part A: Single Ascending Dose (SAD) in healthy male subjects * Part B: Multiple Ascending Dose (MAD) in healthy male subjects
Interventions
- DRUG Placebo
- DRUG FTX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2025-04-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06617546
The ClinicalTrials.gov registry entry for NCT06617546 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Find Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06617546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06617546 about?
NCT06617546 is a clinical study titled "SAD and MAD Study of FTX-101 in Healthy Male Subjects". This is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects. The study will include the following 2 parts: * Part A: Single Ascending Dose (SAD) in healthy male subjects * Part B: Multiple Ascending Dose (MAD) in healthy male s...
What is the current status of trial NCT06617546?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2024-10-14. Estimated completion is 2025-04-17.
What interventions are being tested in trial NCT06617546?
The interventions under investigation include: Placebo (DRUG), FTX-101 (DRUG).
Who is sponsoring clinical trial NCT06617546?
This trial is sponsored by Find Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.